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Abstract
[Aim] In this study, the effect of direct oral anticoagulants (DOACs) on protein C (PC) 
activity was examined using several measuring reagents. 
[Materials and Methods] In total, 90 patients (60 male and ３0 female) with nonvalvular 
atrial fibrillation or venous thromboembolism (VTE) who were on anticoagulation therapy 
with DOACs (rivaroxaban, apixaban, or edoxaban) were studied. The plasma levels of 
PC activity were measured by means of a clotting assay and chromogenic substrate assay, 
using three reagents for each type of assay. 
[Result] Prothrombin time (PT) and activated partial thromboplastin time (APTT) 
were significantly prolonged in a dose-dependent manner in patients who were taking 
rivaroxaban or edoxaban. PC activity, as measured by all three reagents using the clotting 
assay, was influenced only by rivaroxaban, indicating an increase in PC activity in a dose-
dependent manner. Apixaban did not have any influence on the measurements made 
using all three reagents in the clotting assay. On the other hand, none of the three FXa 
inhibitors had any influence on PC activity when it was measured using the three reagents 
in the chromogenic substrate assay. Plasma samples were collected before, as well as 
two and four to eight weeks after rivaroxaban administration in seven patients with AF 
or VTE sequentially. In all three regents using the clotting assay, plasma levels of PC 
activity had increased after the administration of rivaroxaban. On the other hand, all three 
regents using the chromogenic assay had very little influence on PC activity after the 
administration of rivaroxaban.
[Conclusion] The inhibitory effects of the different types of DOACs on clotting activity 
interfere with clotting test measurement systems in patients receiving DOAC therapy. 
When measuring PC activity while the patient is taking rivaroxaban or edoxaban, it is 
necessary to use the chromogenic substrate assay to avoid false highs. Moreover, collecting 
specimens when blood levels of drugs are low, e.g. during the trough phase, whenever 
possible, would be one way to minimize interference.
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Introduction
　Thrombosis is  caused by a combinat ion of 
various environmental factors and genetic factors. 
Thrombophilia is defined as a predisposition condition 
towards thrombosis, and is classified into inherited and 
acquired１). Inherited thrombophilia includes physiologic 
coagulation inhibitors deficiency: antithrombin (AT), 
protein C (PC), and protein S (PS). 
　AT, PC and PS play a central role in control of the 
coagulation system. PC is the zymogen of a vitamin 
K-dependent serine protease and is rapidly activated 
by the thrombin-thrombomodulin complex, becoming 
activated PC (APC). With PS as a cofactor, APC 
inactivates activated factor V (FVa) and activated factor 
VIII (VIIIa) in the presence of phosphatidylserine 
and Ca２+ ２). Inherited PC deficiency is, along with 
AT deficiency and PS deficiency, a key risk factor for 
venous thromboembolism (VTE)３, ４ ). Diagnosis of PC 
deficiency is mainly made by measurements of PC 
activity and antigen levels. Inherited PC deficiency 
involves quantitative and qualitative abnormalities 
in PC caused by a mutation in PROC 5). Inherited 
PC deficiency is classified into type I deficiency, in 
which both the PC antigen level and PC activity level 
are decreased, and type II deficiency, a molecular 
abnormality in which the antigen level is normal 
but activity is decreased6). Type I deficiency is the 
most common (７5-80%). Thus, in the diagnosis of 
PC deficiency, measurement of PC activity is a very 
important test. 
　Treatment of VTE is represented by anti-vitamin 
K antagonists (VKA) or direct oral anticoagulants 
(DOACs). DOACs are indicated for the prevention of 
cerebral infarction due to nonvalvular atrial fibrillation 
(AF), treatment and prevention of recurrent VTE, 
and prevention of VTE following orthopedic surgeries, 
such as joint arthroplasty７-１１). DOACs are classified as 
thrombin inhibitors (dabigatran) and factor Xa inhibitors 
(rivaroxaban, apixaban, edoxaban) according to their 
site of action. Currently, Xa inhibitors are indicated for 
the treatment and prevention of recurrent VTE. The 
DOACs exhibit more predictable pharmacokinetic and 
pharmacodynamic profiles than VKAs; consequently, 
routine coagulation monitoring is not required１２). So, in 
recent years, it is estimated that the use of direct FXa 
inhibitors for VTE has been increasing.
　When conducting screening tests for thrombotic 
d ia thes i s,  inc lud ing inher i ted thrombophi l ia , 
measurements of the activity of protein S (PS), 
antithrombin (AT), and protein C (PC) are essential 
to determine the cause of VTE. When taking warfarin, 
PC, a VK-dependent protein, has reduced activity. 
On the other hand, in recent years, there have been 
reports of false high values of PC activity in patients 
on DOACs, depending on the measurement method 
used１３-１6）. Since it has already been clarified that 
the degree of prolongation of APTT and PT differs 
depending on the DOACs, we thought that PC 
activity value with the reagent using a clotting assay 
would cause a difference depending on the drugs. 
We investigated the effects of the three Xa inhibitors 




　Patients diagnosed with nonvalvular atrial fibrillation 
(AF) or venous thromboembolism (VTE) who attended 
out-patient clinics in the departments of cardiology or 
hematology and were already receiving anticoagulation 
treatment (rivaroxaban, apixaban, or edoxaban) 
were invited to participate in this study. The study 
was approved by the University of Kanazawa Ethics 
Committee (Approval No. 5３0-２ ), and was performed 
in accordance with the ethical principles of the １96４ 
Declaration of Helsinki and its later amendments. 
Written informed consent was obtained from all 
patients before enrollment. Patients with creatinine 
concentrations >２.0 mg/dL and estimated glomerular 
filtration rates <３0 mL/min/１.７３ m２ (according to 
Cockroft-Gault equation) were excluded. Patients were 
also excluded if they had hereditary thrombophilia or 
antiphospholipid antibody syndrome, acute thrombosis, 
severe liver dysfunction, or nephrotic syndrome.
1 ) Sample collection
　Samples were collected in ３.２% sodium-citrate 
tubes and instantly centrifuged to acquire platelet-poor 
plasma. Plasma samples were used in the screening 
tests on the day of collection and were stored at -80℃ 
until their use in specific coagulation assays.
2 ) Coagulation tests
a)　 Prothrombin time (PT) and activated partial 
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thromboplastin time (APTT)
　In all samples, laboratory-based PT and APTT 
were measured using a single reagent (Thromborel S; 
Siemens, Marburg, Germany, and Acitin FSL; Siemens, 
respectively) and the CS-5１00 hemostasis system 
(Sysmex, Kobe, Japan). The normal ranges were PT 
１0.6-１３.0 seconds and APTT ２７.３-４0.３ seconds. 
b)　DOAC concentrations 
　In all samples containing factor Xa (FXa) inhibitors, 
these drug concentrations were estimated using 
Biophen DiXaI (Hyphen BioMed, Neuville-sur-Oise, 
France) with each applied DOAC calibrator and were 
performed using the CS5１00 hemostasis system.
c)　PC activity 
　The level of PC activity was measured by a clotting 
assay and chromogenic substrate assay using three 
reagents for each type of assay. The three reagents 
used for the clotting assay included STA-Staclot Protein 
C (Fujirebio Inc., Tokyo, Japan), Protein C Reagent 
(Siemens), and Hemoclot Protein C (Hyphen BioMed); 
all these tests were performed using the CS5１00 
hemostasis system. Figure １  shows measurement 
principle of the chromogenic substrate assay. In the 
measurement by the chromogenic substrate assay, 
the colorimetric determination by decomposition of 
chromogenic substrate due to APC activated by PC 
activator is performed.
　The three reagents used for the chromogenic 
substrate assay included Test Team S PC (Sekisui 
Medical, Tokyo, Japan), Berichrom Protein C (Siemens), 
and Biophen Protein C (LRT) (Hyphen BioMed); 
these tests were performed using a Coapresta ２000 
coagulation analyzer (Sekisui Medical).
d)　PC antigen
　The level of PC antigen was measured using LPIA-S 
PCII (LSI Medience, Tokyo, Japan) based on a latex 
photometric immunoassay system (STACIA, LSI 
Medience).
3 ) Statistical analysis
　Statistical analysis was performed using the STAT 
VIEW program (Abacus Concepts, Berkeley, CA, 
USA). Pearson product-moment correlation coefficient 
was used to assess the correlation between the 
distribution of PC activity and antigen, as assessed 





　A total of 90 patients (60 male and ３0 female) with 
AF or VTE who were on anticoagulation therapy with 
DOACs. The mean age of patients was 66 ± １４.8 years 
(±SD). Table １  shows disease breakdown of patients. 
The breakdown ７４ patients with af is as follows; ４３ 
alone, ２6 with chronic heart failure (CHF), of ２6 
patients with CHF １6 other diseases (１１ with sick sinus 
syndrome, 5  with atherothrombotic cerebral infarction), 
5  with hypertrophic cardiomyopathy, 5  with deep vein 
thrombosis. Table １  omits the diseases of three or less 
cases. 
2.  Effect of rivaroxaban, apixaban and edoxaban 
on PT and APTT (Fig. 2 )
　First, we examined whether PT and APTT were 
affected by DOACs at different concentrations. We 
demonstrated that PT and APTT were significantly 
prolonged in a dose-dependent manner in patients 
who were taking rivaroxaban or edoxaban. Edoxaban 
resulted in the greatest prolongation of PT as compared 
to the other drugs, and it prolonged PT more than 
APTT (Fig. ２C, r = 0.8３8, p < 0.00１). Similarly, 
Figure.１.  Measurement principle of a chromogenic substrate 
assay
Table １. Characteristics of patients’ diseases and complications
Figure 1. Measurement principle of a chromogenic substrate assay
snake venom
protein C → activated protein C（APC）
APC
p-Glu-Pro-Arg-MNA → p-Glu-Pro-Arg-OH+MNA       
（chromogenic substrate） （methoxynitroanilide）
Disease Cases
Atrial fibrillation Total 74
Af 43
Af & CHF 10
Af, CHF & Sick sinus syndrome 11
Af, CHF & Atherothrombotic cerebral infarction 5
Af & Hypertrophic cardiomyopathy 5
VTE Total 21
DVT 16
DVT & Af 5
Table 1. Characteristics of patients’ diseases and complications 
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Figure 5.  Impact of rivaroxaban, apixaban and edoxaban on PC antigen
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Figure 4.  Impact of rivaroxaban, apixaban and edoxaban on PC activity (Chromogenic assays) 
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Figure 3.  Impact of rivaroxaban, apixaban and edoxaban on PC activity (Clotting assays) 
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A. Rivaroxaban C. EdoxabanB. Apixaban
D. Rivaroxaban F. EdoxabanE. Apixaban
rivaroxaban resulted in the greatest prolongation of 
APTT as compared to the other drugs, and it prolonged 
APTT more than PT (Fig.２D, r = 0.85１, p < 0.00１). On 
the other hand, apixaban did not influence either PT 
(Fig. ２B, r = 0.１58, p = 0.３96) or APTT (Fig. ２E, r = 
0.４0４, p = 0.06２) regardless of drug concentration.
3.  Effect of rivaroxaban, apixaban and edoxaban 
on PC activity (Fig. 3, Fig. 4, Table 2) 
　PC activity was measured by a clotting assay using 
three reagents. The results showed that PC activity, as 
measured by all three reagents, was influenced only by 
rivaroxaban, indicating an increase in PC activity in a 
dose-dependent manner (Fig. ３A). In particular, the 
PC activity measured using the STA-Staclot Protein C 
reagent was most affected by rivaroxaban (r = 0.695, 
p < 0.00１), and that measured using the Hemoclot 
Protein C reagent was least affected by rivaroxaban (r 
= 0.３７8, p = 0.0３9). PC activity assessments performed 
using Protein C Reagent were slightly, but not 
significantly, affected by the use of edoxaban (r = 0.３４１, 
p = 0.0７6) (Fig. ３C). On the other hand, apixaban did 
not have any influence on the measurements made 
using Hemoclot Protein C and Protein C Reagent (Fig. 
３B).
　None of the three FXa inhibitors had any influence 
on PC activity when it was measured using the three 
reagents in the chromogenic substrate assay (Fig. ４, 
Table ２ ). 
4.  Effect of rivaroxaban, apixaban and edoxaban 
on PC antigen (Fig. 5, Table 2)
　As with the previous assays, none of the three FXa 
inhibitors had any influence on the amount of PC 
antigen measured in assays based on the principles of 
the latex agglutination assay (rivaroxaban: r = 0.４１0, p 
= 0.１４6, apixaban: r = -0.１0３, p = 0.5７6, edoxaban: r = 
-0.0３9, p = 0.8４6). 
5.  The changes in PC activity and plasma 
rivaroxaban concentrations before and after 
rivaroxaban administration
　Plasma samples were collected before, as well 
Figure.2.  Impact of rivaroxaban, apixaban and edoxaban on PT 
and APTT
Figure.4.  Impact of rivaroxaban, apixaban and edoxaban on PC 
activity (Chromogenic assays) 
Figure.5.  Impact of rivaroxaban, apixaban and edoxaban on PC 
antigen
Figure.3.  Impact of rivaroxaban, apixaban and edoxaban on PC 
activity (Clotting assays) 
Table 2. Relationships between plasma concentrations of 
DOACs and plasma levels of PC activity and antigen
Table 2. Relationships between plasma concentrations of DOACs and 
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as two and four to eight weeks after rivaroxaban 
administration in seven patients with AF or VTE 
sequent ia l ly.  As shown in Fig . 6 , the plasma 
concentration of rivaroxaban was ２0-500 ng/mL after 
the drug administration. Compared to baseline, both 
PT and APTT were significantly prolonged after the 
administration of rivaroxaban. 
　In all three regents using the clotting assay (Fig. 
７A), plasma levels of PC activity were increased after 
the administration of rivaroxaban. The Interference 
was more pronounced in the STA Staclot Protein C as 
compared to Protein C Regent. On the other hand, all 
three regents using the chromogenic assay had very 
little influence on PC activity after the administration of 
rivaroxaban (Fig. ７B). 
Discussion
　DOACs affect commonly used global coagulation 
assays (PT and APTT) １5,１７) and therefore influence 
coagulation function assays such as thrombophilia 
or lupus anticoagulant. On the basis of the current 
literature for the DOACs’ effects on the coagulation 
times, the PT may be relatively sensitive (as compared 
with the APTT) to FXa inhibitors, and the APTT 
may be relatively sensitive (as compared with the 
PT) to dabigatran concentration１３,１8,１9). Our study 
shows that PT and APTT were significantly prolonged 
by edoxaban and rivaroxaban. On the other hand, 
apixaban did not influence PT or APTT regardless of 
the concentration. As with previous reports, increasing 
concentrations of apixaban and rivaroxaban prolong PT 
or APTT incrementally２0,２１). The variation may be due 
to the physical and/or chemical interactions between 
individual FXa inhibitors and phosphatidylserine found 
within these thromboplastin reagents. Also, the PT and 
APTT prolongation of apixaban were milder than those 
of the other two drugs. It might be considered that the 
difference in Ki value is involved.
　Two different methods were used to measure PC 
activity, namely, clotting assays and chromogenic 
substrate assays. In commercial assays, both clotting 
and chromogenic types of assays use a snake venom 
activator to convert the plasma PC to APC. The 
clotting‐based assays utilize mainly the APTT, and PC 
activity is detected using the prolongation in clotting 
time resulting from inactivation of FVa and FVIIIaby 
APC (APTT prolongation effect). Therefore, APTT 
prolongation overestimate the PC value in plasma8,１5,１8). 
In contrast, the chromogenic assay is based on the 
addition of chromogenic substrate to the generated 
APC in the diluted plasma sample. The formation of 
chromogenic color is proportional to the amount of 
APC in the plasma sample. Therefore, the chromogenic 
assays are not influenced by prolongation of the clotting 
time２２).
　PC activity values with the three reagents used in 
the clotting assays in this study showed significantly 
positive correlations with plasma concentrations of 
rivaroxaban (Fig. ３A). Among them, PC activity was 
affected most by rivaroxaban when the STA-Staclot 
Protein C reagent was used (Fig. ３A). With edoxaban, 
PC activity tended to show a positive correlation with 
plasma concentrations of the drug when Protein C 
Reagent was used, although the difference was not 
significant (Fig. ３C). With apixaban, on the other 
hand, almost no effect on PC activity was seen with 







前 後1 後2Before   After   After








前 後1 後2Before   After   After














































Before   After   After
2W     4-8W
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C Reagent) used in the clotting assays (Fig. ３B). 
With rivaroxaban, prolongation of APTT in particular 
was conspicuous, as shown in Fig. ２D, suggesting 
that PC activity showed greater false high values with 
rivaroxaban as compared to edoxaban and apixaban. As 
shown in Fig. ２E, APTT did not increase at all with 
apixaban, suggesting that this drug has almost no effect 
on PC activity measurements in the clotting assay. In 
patients on FXa inhibitor therapy, PC activity levels 
are reported to be falsely elevated with all reagents 
when using clotting assay２２), although only rivaroxaban 
showed dose-dependent false high values in our study. 
Almost no effect was seen with apixaban. One reason 
for the differences in measured PC activity according 
to the type of reagent used for the assay is thought to 
be that the APTT prolongation effect differs depending 
on the composition of the reagent. The APTT‐based 
assays are influenced by the phosphatidylserine source 
and concentration.
　Although we did not investigate the thrombin 
inhibitor dabigatran in this study, the antithrombin 
effect of dabigatran is better reflected by APTT than 
PT２３-２5), due to greater false high values of PC activity 
with clotting assays.
　In contrast, PC activity measurements were not 
affected by any of the three direct FXa inhibitors 
(r ivaroxaban, apixaban, and edoxaban) in the 
chromogenic substrate assays using the three reagents. 
Similarly, PC antigen levels measured using a latex 
photometric immunoassay system were not shown to be 
affected by the three FXa inhibitors (Fig. 5 ). Thus, in 
patients receiving these FXa inhibitors, measurements 
of PC activity with the chromogenic substrate assay 
and antigen levels are thought to be unaffected by the 
FXa inhibitor being used.
　There are two types of congenital PC deficiency: 
type I, in which both PC activity and antigen levels 
are decreased (quantitative defect), and type II, in 
which PC activity is decreased but antigen levels 
are normal (qualitative defect)6). The role of the PC 
antigen assay is to distinguish between type I and type 
II deficiencies when a defect in PC function is found. 
Comparison of the ratio of PC activity and PC antigen 
values can differentiate type I from type II. Thus, type 
II PC deficiency might be missed by measurements 
of antigen levels alone. Hence, when screening for 
congenital thrombophilia, PC activity always needs 
to be measured. Further, our results suggest that in 
screening tests for congenital thrombophilia in patients 
on DOACs, PC activity should probably be measured 
using chromogenic substrate analysis.
　As shown above, the inhibitory effects of the 
different types of DOACs on clotting activity interfere 
with clotting test measurement systems in patients on 
DOAC therapy. Therefore, when measuring the activity 
of the various anticoagulant factors in screening tests 
for congenital thrombophilia, it is possible that results 
that should show low values instead show high values, 
preventing accurate diagnosis. While it would be 
better to perform the tests after discontinuing DOACs, 
it is often difficult to discontinue DOAC treatment. 
Collecting specimens when blood levels of drugs are 
low, e.g. during the trough phase, whenever possible, 
would be one way to minimize interference１8,２5). 
In addition, a reagent called “DOAC Stop”, which 
neutralizes anticoagulant activity in specimens, has 
recently become available２6,２７), allowing clotting assays 
to be performed while excluding the effects of DOACs.
　In conclusion, plasma levels of PC activity are 
affected by the type of DOACs and the measurement 
principles. Moreover, even when reagents having 
the same measurement principle are used, the effect 
on measured levels differs for each reagent. When 
screening for congenital thrombophilia in patients on 
DOAC therapy, a good understanding of not only the 
principles and characteristics of reagents, but also 
parameters specific to DOACs (pharmacological activity, 
inhibitory mechanism, inhibition constant Ki value, 
factors affecting reactivity to reagents)２１,２5,２8-３0) and other 
factors is necessary, and steps should be taken to limit 
the effects of these drugs to the extent possible.
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ならびに PT・APTT，PC 活性（凝固時間法を用いた ３ 試薬ならびに合成基質法を用い
た ３ 試薬），PC 抗原量をそれぞれ測定した。リバーロキサバン治療前後で検体を採取で
きた ７ 症例についても，同様に薬剤血中濃度ならびに PC 活性を測定し，薬剤の影響を
検討した。
【結果】DOAC の中でも特にリバーロキサバンは，凝固時間法で測定した PC 活性値に影
響を及ぼし，偽高値となった。一方，アピキサバンは全く PC 活性値に影響しなかった。
合成基質法による PC 活性値ならびに PC 抗原量は，３ 剤とも DOAC の影響をうけなかっ
た。また，リバーロキサバンの治療前後で PC 活性を測定したところ，凝固時間法を用い
た測定法では薬剤血中濃度の増加に伴い １.２ 〜 １.5 倍程度偽高値となった。一方，合成基
質法を用いた測定法では，PC 活性値はほとんど治療前後で変化しなかった。
【考察】以上の結果から，リバーロキサバンとエドキサバン内服中に PC 活性を測定する場
合は，偽高値をさけるために，合成基質法を用いる必要がある。また，薬剤血中濃度が低
下したタイミングで検体を採取し，薬剤の影響を極力除くことが重要である。
